Better Biomarkers for Pancreatic Diseases.
Better Biomarkers for Pancreatic Diseases.
复制标题
更好的胰腺疾病生物标志物。
DOI:
10.1097/mpa.0000000000000550
复制
发表时间:
2015
期刊:
影响因子:
2.9
通讯作者:
Whitcomb,DavidC
中科院分区:
文献类型:
--
作者:
Whitcomb,DavidC
Physicians struggle to evaluate the human pancreas—an organ tucked in the retroperitoneal space behind the stomach and intestines where it is inaccessible to physical examination. Pancreatic disorders remain difficult to detect at early stages and have complex and highly variable clinical courses. The major nonmalignant chronic diseases of the exocrine pancreas can be broadly divided into 4 categories. Infectious pancreatitis occurs but is uncommon, and traumatic injury can trigger pancreatitis but accounts for a minority of cases. Monogenetic Mendelian disorders of the pancreas including cystic fibrosis, hereditary pancreatitis, and familial pancreatitis are well known, but together, these account for a fraction of the burden of disease. The majority of exocrine pancreatic diseases fall into the fourth category. They include multiple, progressive, complex disorders that appear randomly in some individuals, presenting as recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), or pancreatic neoplasms. Pancreatic neoplasms typically occur independent of clinically evident inflammation, and detection occurs at late stages because their development is also unexpected. Thus, complex disorders represent the majority of pancreatic disease; their unexpected occurrence, unpredictable clinical course, and paucity of effective targeted treatment make clinical evaluation and management challenging.